SARS-CoV-2 ORF10 Antibody [mFluor Violet 450 SE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-11939MFV450
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
SARS-CoV-2
Applications
ELISA
Label
mFluor Violet 450 SE (Excitation = 406 nm, Emission = 445 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Antibody was raised against a peptide corresponding to 13 amino acids near the carboxyl terminus of SARS-CoV-2 ORF10 protein. The immunogen is located within the last 50 amino acids of the SARS-CoV-2 ORF10 protein.
Specificity
Antibody is predicted to not cross-react with other coronavirus family members.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for SARS-CoV-2 ORF10 Antibody [mFluor Violet 450 SE]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Peptide affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: SARS-CoV-2 ORF10
Functionally, SARS-CoV-2 ORF10 is suggested to interact with the Cullin 2 RING E3 ligase complex, indicating that ORF10 might promote viral pathogenesis by taking over the ubiquitination machinery (4, 5). Additionally, the SARS-CoV-2 ORF10 gene appears to be differentially expressed based on COVID-19 severity. For example, ORF10 appears to be highly expressed in the infected cells from severe cases while it is either lowly expressed or not detectable in cells infected from moderate cases (6). Therefore, ORF10 expression could be indicative of COVID-19 progression (6).
References
1. Michel, C. J., Mayenr, C., Poch, O., & Thompson, J. D. (2020). Characterization of accessory genes in coronavirus genomes. Virology journal. https://doi.org/10.1186/s12985-020-01402-1
2. Uniprot (A0A6B9W2G5)
3. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The protein journal. https://doi.org/10.1007/s10930-020-09901-4
4. Hassan, S., Attrish, D., Ghosh, S., Choudhury, P., Uversky, V., Uhal, B., Lundstrom, K., Rezaei, N., Aljabali, A., Seyran, M., et al. (2020). Notable sequence homology of the ORF10 protein introspects the architecture of SARS-COV-2. bioRxiv. 10.1101/2020.09.06.284976.
5. Ahmadpour, D., & Ahmadpoor, P. (2020). How the COVID-19 Overcomes the Battle? An Approach to Virus Structure. Iranian journal of kidney diseases.
6. Liu, T., Jia, P., Fang, B., & Zhao, Z. (2020). Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case Severity. Frontiers in microbiology. https://doi.org/10.3389/fmicb.2020.603509
Alternate Names
2019-nCoV ORF10, 2019-nCoV ORF10 Protein, COVID-19 ORF10, Human coronavirus ORF10 Protein, ORF10, ORF10 protein, SARS-CoV-2, SARSCoV2 ORF10 Protein, SARS-CoV-2 ORF10 Protein, Severe Acute Respiratory Syndrome Coronavirus 2 ORF10 Protein
Gene Symbol
ORF10
Additional SARS-CoV-2 ORF10 Products
Product Documents for SARS-CoV-2 ORF10 Antibody [mFluor Violet 450 SE]
Product Specific Notices for SARS-CoV-2 ORF10 Antibody [mFluor Violet 450 SE]
mFluor(TM) is a trademark of AAT Bioquest, Inc. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...